---
title: "Enveric Biosciences Inc reports results for the quarter ended December 31 - Earnings Summary"
description: "Enveric Biosciences IncQ) reported a quarterly adjusted loss of $4.80 per share for the quarter ended December 31, significantly higher than last year's loss of $22.05 per share. The company reported "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/233698277.md"
published_at: "2025-03-28T23:01:01.000Z"
---

# Enveric Biosciences Inc reports results for the quarter ended December 31 - Earnings Summary

> Enveric Biosciences IncQ) reported a quarterly adjusted loss of $4.80 per share for the quarter ended December 31, significantly higher than last year's loss of $22.05 per share. The company reported zero revenue and a total loss of $3.16 million. Shares fell by 70.2% this quarter. Analysts' earnings estimates had risen by 96.2% in the last three months, with a current average rating of "buy". The median 12-month price target is $54.80.

-   Enveric Biosciences Inc (ENVB.OQ) reported a quarterly adjusted loss of $4.80​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-22.05. The lone analyst forecast for the quarter was for a loss of 23 cents per share.
    
-   Reported revenue was zero​; analysts expected zero.
    
-   Enveric Biosciences Inc’s reported EPS for the quarter was a loss of $4.80​.
    
-   The company reported a quarterly loss of $3.16 million.
    
-   Enveric Biosciences Inc shares had fallen by 70.2% this quarter. FORECAST CHANGES
    
-   The mean earnings estimate of analysts had risen by about 96.2% in the last three months.​
    
-   In the last 30 days, there have been no earnings estimate revisions by analysts covering the company. RECOMMENDATIONS
    
-   The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 1 “strong buy” or “buy,” no “hold” and no “sell” or “strong sell.” The average consensus recommendation for the biotechnology & medical research peer group is also “buy”
    
-   Wall Street’s median 12-month price target for Enveric Biosciences Inc is $54.80 This summary was machine generated from LSEG data March 28 at 11:00 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
    

### MISSED

Dec. 31 2024 -0.23 -4.80 Missed

Sep. 30 2024 -7.80 -3.60 Beat

Jun. 30 2024 -8.25 -3.75 Beat

Mar. 31 2024 -11.62 -9.15 Beat

### Related Stocks

- [ENVB.US - Enveric Biosciences](https://longbridge.com/en/quote/ENVB.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Aygaz Proposes To Pay Cash Dividend At Gross 12.55 Lira Per Share For 2025 | AYGAZ :SAID ON FRIDAY, PROPOSES TO PAY CASH DIVIDEND AT GROSS 12.55 LIRA, NET 10.67 LIRA PER SHARE FOR 2025 Source text  | [Link](https://longbridge.com/en/news/276033091.md) |
| Barka Desalination FY Dividend Upto 12 Baisas Per Share | BARKA DESALINATION COMPANY SAOGM):BARKA DESALINATION FY CASH DIVIDEND UPTO 12 BAISAS PER SHARE | [Link](https://longbridge.com/en/news/276300063.md) |
| 12:01 ETAstroTurf® Great Lakes Named Distributor of the Year | AstroTurf® has awarded AstroTurf Great Lakes the title of Distributor of the Year, recognizing their exceptional perform | [Link](https://longbridge.com/en/news/276360364.md) |
| The Analyst Verdict: Tenet Healthcare In The Eyes Of 12 Experts | Twelve analysts have recently evaluated Tenet Healthcare (NYSE:THC), providing a mix of bullish and bearish opinions. Th | [Link](https://longbridge.com/en/news/276493220.md) |
| Deep Dive Into Docusign Stock: Analyst Perspectives (12 Ratings) | Docusign (NASDAQ:DOCU) has been analyzed by 12 analysts, revealing a mix of bullish and bearish sentiments. The average  | [Link](https://longbridge.com/en/news/276266170.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.